Study identifies novel pathway with potential to slow the progression of pulmonary fibrosis
Researchers have found a potential new way to slow the progression of lung fibrosis and other fibrotic diseases by inhibiting ...
Lung conditions: New AI test set to transform diagnosis
A rapid test harnessing the power of AI is set to transform the diagnosis of a lung condition that affects 3 million people ...
Medical Xpress4d
Scientists discover immune cell networks driving deadly lung disease
Get Instant Summarized Text (Gist) Researchers have identified networks of misplaced immune cells, particularly plasma cells, driving idiopathic pulmonary fibrosis (IPF), a fatal lung disease ...
Medical Xpress on MSN6d
People with COPD and arthritis have an increased risk of death, reveals research
People with chronic obstructive pulmonary disease (COPD) and arthritis have a higher risk of death than people with arthritis ...
Dupixent® (dupilumab) Approved as the First-ever Biologic Medicine in Japan for Patients with Chronic Obstructive Pulmonary Disease (COPD)
Following recent approvals in the EU, China and the U.S., this approval was based on pivotal Phase 3 results in adults with elevated eosinophils ...
Press Release: Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD
Dupixent approved as the first-ever biologic medicine in Japan for patients with COPDFollowing recent approvals in the EU, China, and the US, ...
Medscape13d
Evidence Growing That GLP-1RAs May Reduce COPD Exacerbations and Risks for Other Lung Diseases
Emerging evidence shows glucose-lowering medications may have the potential to improve chronic obstructive pulmonary disease ...
Pharmabiz2d
Sanofi & Regeneron’s Dupixent receives Japanese marketing approval to treat patients with COPD
Sanofi & Regeneron’s Dupixent receives Japanese marketing approval to treat patients with COPD: Paris Saturday, March 29, 2025, 09:00 Hrs [IST] The Ministry of Health, Labour an ...